Experiences with Porcine and Salmon Calcitonin in the Treatment of Paget’s Disease

  • Stanley Wallach


The development of calcitonin (CT) as the first effective therapeutic agent for Paget’s disease is not just of historic significance but also of current interest as the most effective treatment for Paget’s disease available in the United States. Calcitonin, in fact, has provoked the reawakening of interest in Paget’s disease during the past two decades, 100 years after Sir James Paget’s description in the late 1800s. Agents used in the 1940–1960 era, such as corticosteroids, sodium fluoride, estrogens, and aspirin, have not stood the test of time since none produced the spectacular effects that were so evident with CT. The rapidity, within a decade, with which the discovery of CT was translated into effective treatment by collaboration among basic researchers, clinical investigators, and industrial research and development groups is awesome.


Salmon Calcitonin Urinary Hydroxyproline Bone Blood Flow Calcitonin Treatment Pagetic Bone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Copp DH: Calcitonin comes of age: A quarter century in perspective, in Pecile A (ed): Calcitonin: Chemistry, Physiology, Pharmacology and Clinical Aspects. Amsterdam, Elsevier Science Publishing, 1985; pp 3–9.Google Scholar
  2. 2.
    Hirsch PF, Munson PL: Thyrocalcitonin. Physiol Rev 1969; 49: 548–622.PubMedGoogle Scholar
  3. 3.
    Foster GV, Baghdiantz A, Kumar MA, et al: Thyroid origin of calcitonin. Nature 1964; 202: 1303–1305.PubMedCrossRefGoogle Scholar
  4. 4.
    Bijvoet OLM, van der Sluys Veer J, Jansen AP: Effects of calcitonin on patients with Paget’s disease, thyrotoxicosis, or hypercalcemia. Lancet 1986; 1: 876–881.Google Scholar
  5. 5.
    Caniggia A, Nuti R, Galli M, et al: Effect of a long-term treatment with the aminosuberic analog of eel calcitonin on osteocalcin in Paget’s disease. Panminerva Med 1987; 29: 1–5.PubMedGoogle Scholar
  6. 6.
    Chausmer AB, Chavez C, Wain RM, Dakka Y: Calcitonin, zinc and testicular function. Metabolism 1989; 38: 714–717.PubMedCrossRefGoogle Scholar
  7. 7.
    DeRose J, Singer FR, Avramides A, et al: Response of Paget’s disease to porcine and salmon calcitonins. Am J Med 1974; 56: 858–866.PubMedCrossRefGoogle Scholar
  8. 8.
    Shai F, Baker RK, Wallach S: The clinical and metabolic effects of porcine calcitonin on Paget’s disease of bone. J Clin Invest 1971; 50: 1927–1939.PubMedCrossRefGoogle Scholar
  9. 9.
    Wallach S, Avramides A, Flores A, et al: Skeletal turnover and total body elemental composition during extended calcitonin treatment of Paget’s disease. Metabolism 1975; 24: 745–753.PubMedCrossRefGoogle Scholar
  10. 10.
    Toh SH, Claunch BC, Brown PH: Effect of calcitonin treatment on the natural course of bone demineralization in Paget’s disease. J Clin Endocrinol Metab 1983; 56: 405–409.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen JR, Rhee RSC, Wallach S, et al: Neurologic disturbances in Paget disease of bone: Response to calcitonin. Neurology 1979; 29: 448–457.PubMedGoogle Scholar
  12. 12.
    El Samma M, Linthicum FH Jr, House HP, House JW: Calcitonin as treatment for hearing loss in Paget’s disease. Am J Otol 1986; 7: 241–243.Google Scholar
  13. 13.
    Meyers M, Singer FR: Osteotomy for tibia vera in Paget’s disease under cover of calcitonin. J Bone Joint Surg 1978; 60; 1;(A): 810–814.PubMedGoogle Scholar
  14. 14.
    Weisz GM: Lumbar canal stenosis in Paget’s disease: The staging of the clinical syndrome, its diagnosis, and treatment. Clin Orthop 1986; 206: 223–227.PubMedGoogle Scholar
  15. 15.
    Avramides A, Flores A, DeRose J, Wallach S: Treatment of Paget’s disease of bone with once a week injections of salmon calcitonin. Br Med J 1975; 3: 632.PubMedCrossRefGoogle Scholar
  16. 16.
    Avramides A, Flores A, DeRose J, Wallach S: Paget’s disease of the bone: Observations after cessation of long-term synthetic salmon calcitonin treatment. J Clin Endocrinol Metab 1976; 42: 459–463.PubMedCrossRefGoogle Scholar
  17. 17.
    O’Donoghue DJ, Hosking DJ: Biochemical response to combination of disodium etidronate with calcitonin in Paget’s disease. Bone 1987; 8: 219–225.PubMedCrossRefGoogle Scholar
  18. 18.
    Reginster JY, Jeugmans-Huynen AM, Albert A, et al: One year’s treatment of Paget’s disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Mineral Res 1988; 3: 249–252.CrossRefGoogle Scholar
  19. 19.
    Gagel RF, Logan C, Mallette LE: Treatment of Paget’s disease of bone with salmon calcitonin nasal spray. J Am Geriatr Soc 1988; 36: 1011–1014.Google Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • Stanley Wallach

There are no affiliations available

Personalised recommendations